Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Charite University, Berlin, Germany Stanley Medical Research Institute |
---|---|
Information provided by: | Charite University, Berlin, Germany |
ClinicalTrials.gov Identifier: | NCT00148590 |
The purpose of this study is to evaluate the efficacy and safety of memantine as add-on treatment for the prevention of negative symptomatology in patients with an acute exacerbation of schizophrenia.
Primary outcome parameter are negative symptoms after 6 months
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Memantine Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Memantine for the Prevention of Negative Symptomatology and Cognitive Impairment in Schizophrenia |
Estimated Enrollment: | 40 |
Study Start Date: | November 2005 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Memantine
Daily dose of 10mg memantine Vs. Placebo
|
Placebo: Placebo Comparator |
Drug: Placebo
Daily dose of 10mg memantine Vs. Placebo
|
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Martin Schaefer, MD | +49-201-174-2200 | martin.schaefer@charite.de |
Germany | |
Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy | Recruiting |
Berlin, Germany, 10117 | |
Contact: Michael Krebs, MD +49-30-450-517198 michael.krebs@charite.de | |
Contact: Karolina Leopold, MD +49-30-450-517198 karolina.leopold@charite.de | |
Sub-Investigator: Michael Krebs, MD | |
Sub-Investigator: Karolina Leopold, MD |
Principal Investigator: | Martin Schaefer, MD | Charite Campus Mitte; Dept. of Psychiatry and Psychotherapy and Department of Psychiatry, Kliniken Essen-Mitte, Essen |
Responsible Party: | Charite University, Berlin, Germany ( Martin Schaefer, MD ) |
Study ID Numbers: | MIND 1, 02T-247 (SMRI) |
Study First Received: | September 7, 2005 |
Last Updated: | September 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00148590 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Memantine Negative syndrome Schizophrenia Cognitive impairment Glutamate |
Schizophrenia Excitatory Amino Acids Dopamine Mental Disorders |
Memantine Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs Antiparkinson Agents |
Excitatory Amino Acid Agents Dopamine Agents Central Nervous System Agents Pharmacologic Actions Excitatory Amino Acid Antagonists |